Key facts: Gilead shares up 3.3% on positive HIV trial; drug prices to drop
I'm PortAI, I can summarize articles.
Gilead Sciences' shares rose 3.3% following positive phase III trial results for a new HIV treatment combining bictegravir and lenacapavir, meeting its primary goal.1Gilead Sciences will lower drug prices for Medicaid and offer discounts for cash customers through TrumpRx.gov, including its hepatitis C treatment, Epclusa.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments